米卡芬净联合伏立康唑治疗血液肿瘤侵袭性真菌病患者的临床分析

Clinical Analysis of Micafungin Combined with Voriconazole in the Treatment of Hematological Tumor Patients with Invasive Fungal Disease

目的:探讨米卡芬净联合伏立康唑治疗血液肿瘤侵袭性真菌病(invasive fungal disease,IFD)患者的临床疗效及安全性。方法:回顾性分析2019年6月至2020年6月中国医学科学院肿瘤医院深圳医院接受米卡芬净联合伏立康唑抗真菌治疗的30例IFD患者的临床资料,设为观察组,并选择同期单药应用伏立康唑抗真菌治疗的30例IFD患者设为对照组,两组患者基数水平相当具有可比性,评价观察组和对照组的疗效及不良反应。结果:观察组治疗中位时间16.5天(7~52天),治疗有效率86.7%,发生不良反应率16.7%,对照组治疗中位时间22天(7~56天),治疗有效率63.3%,发生不良反应率20%,观察组治疗中位时间少于对照组,治疗有效率高于对照组,差异均有统计学意义(P<0.05)。不良反应发生率略小于对照组,差异无统计学意义(P>0.05)。结论:米卡芬净联合伏立康唑治疗IFD安全有效,值得临床选择。

Objective:To evaluate the efficacy and safety of micafungin and voriconazole in the treatment of hematological tumor patients with invasive fungal disease(IFD).Methods:A retrospective analysis of the clinical data was conducted for 60 patients with IFD from National Cancer Center/National Clinical Research Cancer for Cancer/Cancer Hospital&Shenzhen Hospital between June 2019 and June 2020.A total of 30 cases were assigned to the observation group,and another 30 cases to the control group.The observation group was treated with micafungin and voriconazole,while the control group was treated with voriconazole.Efficiency and adverse reactions in the two groups were compared.Results:The median treatment time in the observation group was 16.5 days(7 to 52 days)which was shorter than that in the control group[22 days(7 to 56 days),P<0.05];the overall efficacy rate in the former was 86.7%which was higher than that in the latter(16.7%,P<0.05);and the adverse reaction rate in the former was 16.7%which was lower than that in the latter(20%,P>0.05).Conclusion:The combination therapy of micafungin and voriconazole is predominant in efficiency and safety than micafungin alone,which is worthy of further clinical application.